Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05889156Phase 2Completed

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

Role: lead

NCT04052516Phase 2Completed

A Phase 2b Study of Icosabutate in Fatty Liver Disease

Role: lead

NCT05919680Phase 2Recruiting

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Role: lead

NCT05181085Phase 1Completed

Study of NST-6179 in Healthy Subjects

Role: lead

NCT05368831Phase 1Completed

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects

Role: lead

NCT04630366Phase 1Completed

A Phase 1, First Time in Humans Study of NST-1024

Role: lead

NCT03577275Phase 1Completed

A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval

Role: lead

All 7 trials loaded